Introducing Lenivia
20 Nov 2026
Zoetis Learning Academy
Chronic pain is multifactorial, and not every patient responds the same way to familiar options. This session introduces Lenivia - a canine monoclonal antibody (mAb) that specifically targets and neutralises nerve growth factor (NGF) to effectively reduce OA pain for 3 months. This session will identify where Lenivia may fit within a practical, stepwise approach to long-term pain management. We’ll cover the key clinical considerations for patient selection, setting expectations with owners, and how to monitor response and adjust the plan over time.
- Describe where Lenivia may sit within a stepwise, multimodal chronic pain management plan.
- Identify suitable patients and key considerations for initiating therapy in practice.
- Outline practical monitoring points and how to assess response over time, including when to adjust the treatment plan
){kind=logo}
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
)
)
)
){kind=logo}
){kind=logo}
